A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach
Language: 
English
Short Title: 
A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics
Abstract: 

Evidence-based medicine (EBM) is a broad concept, but the key elements include the incorporation of clinical judgment (which requires clinical experience) together with relevant scientific evidence while remaining mindful of the individual patient's values and preferences. Using the framework and philosophy of EBM, this systematic review summarizes the pharmacology, efficacy, and tolerability of newly approved oral antipsychotics, including iloperidone, asenapine, and lurasidone, and outlines what is known about agents that are in late-stage clinical development, such as cariprazine, brexpiprazole, zicronapine, bitopertin, and EVP-6124. Potential advantages and disadvantages of these agents over existing antipsychotics are outlined, centered on clinically relevant issues such as the potential for weight gain and metabolic abnormalities, potential association with somnolence/sedation, extra-pyramidal side effects, akathisia, and prolongation of the electrocardiogram (ECG) QT interval, as well as practical issues regarding dosing instructions, titration requirements, and drug-drug interactions. Lurasidone appears to be best in class in terms of minimizing untoward alterations in body weight and metabolic variables. However, iloperidone, asenapine, lurasidone, and cariprazine differ among themselves in terms of on-label dosing frequency (once daily for lurasidone and, presumably, cariprazine versus twice daily for iloperidone and asenapine), the need for initial titration to a therapeutic dose for iloperidone and possibly cariprazine, requirement to be taken sublingually for asenapine, requirement for administration with food for lurasidone, lengthening of the ECG QT interval (greater for iloperidone than for asenapine and no effect observed with lurasidone), and adverse effects such as akathisia (seen with cariprazine, lurasidone, and asenapine but not with iloperidone) and sedation (most notable with asenapine).

Author(s): 
Citrome, Leslie
Item Type: 
Journal Article
Publication Title: 
CNS drugs
Journal Abbreviation: 
CNS Drugs
Publication Date: 
2013-11
Publication Year: 
2013
Pages: 
879-911
Volume: 
27
Issue: 
11
ISSN: 
1179-1934
DOI: 
10.1007/s40263-013-0105-7
Library Catalog: 
PubMed
Extra: 
PMID: 24062193

Turabian/Chicago Citation

Leslie Citrome. 2013-11. "A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach." CNS drugs 27: 11: 879-911. 10.1007/s40263-013-0105-7.

Wikipedia Citation

<ref> {{Cite journal | doi = 10.1007/s40263-013-0105-7 | issn = 1179-1934 | volume = 27 | pages = 879-911 | last = Citrome | first = Leslie | coauthors = | title = A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach | journal = CNS drugs | date = 2013-11 | pmid = | pmc = }} </ref>